PNAS: Modified CRISPR Inserts XIST Silencer into Extra Chromosome 21 in Down Syndrome Stem Cells

Researchers led by Volney Sheen at Beth Israel Deaconess Medical Center and Harvard Medical School publish proof-of-concept work in the Proceedings of the National Academy of Sciences demonstrating that a modified CRISPR-Cas9 system can insert the 14-kilobase XIST gene into the extra copy of chromosome 21 in human induced pluripotent stem cells (iPSCs), partially silencing the extra chromosome's activity. XIST is the long non-coding RNA naturally responsible for X-chromosome inactivation in female cells — the team repurposed it to silence the trisomy chromosome. The modified approach (using an engineered integration strategy) achieved 20–40% insertion efficiency, a ~30-fold improvement over conventional CRISPR integration approaches for large cargo. The XIST gene silenced a significant fraction of chromosome 21 gene expression in cells where insertion succeeded. Important caveats: experiments were limited to iPSC lines, partial chromosome silencing was achieved rather than complete, off-target analysis requires further work, and animal model testing has not yet been reported. Down syndrome affects ~1 in 640 U.S. births (~220,000 Americans). Currently no treatments address its underlying genetic cause. While clinical application remains years to decades away, this is the first published demonstration that CRISPR can be used to attempt chromosome-level silencing for trisomy.